Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.965 USD | +14.88% | -11.58% | -96.91% |
19/04 | Sunshine Biopharma Unit Receives Health Canada Approval for Biosimilar Product | MT |
19/04 | Top Premarket Decliners | MT |
Sales 2024 * | 44.4M 3.71B | Sales 2025 * | 100M 8.34B | Capitalization | 835K 69.71M |
---|---|---|---|---|---|
Net income 2024 * | - 0 | Net income 2025 * | 12M 1B | EV / Sales 2024 * | 0.02 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.01 x |
P/E ratio 2024 * |
1.09
x | P/E ratio 2025 * |
0.08
x | Employees | 44 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.55% |
1 day | +0.30% | ||
1 week | -11.58% | ||
Current month | -4.00% | ||
1 month | -91.76% | ||
3 months | -96.35% | ||
6 months | -97.10% | ||
Current year | -96.91% |
Managers | Title | Age | Since |
---|---|---|---|
Steve Slilaty
CEO | Chief Executive Officer | 71 | 15/09/15 |
Camille Sebaaly
DFI | Director of Finance/CFO | 62 | 15/09/15 |
Marc Beaudoin
COO | Chief Operating Officer | - | 25/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Natan
BRD | Director/Board Member | 70 | 01/22/01 |
Steve Slilaty
CEO | Chief Executive Officer | 71 | 15/09/15 |
Camille Sebaaly
DFI | Director of Finance/CFO | 62 | 15/09/15 |
Date | Price | Change | Volume |
---|---|---|---|
03/24/03 | 0.84 | +0.30% | 4 994 404 |
02/24/02 | 0.8375 | -2.64% | 2,975,571 |
01/24/01 | 0.8602 | -1.69% | 2,405,593 |
30/24/30 | 0.875 | +1.93% | 7,435,351 |
End-of-day quote Nasdaq, May 03, 2024
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-96.91% | 835K | |
+31.52% | 662B | |
+21.96% | 546B | |
-5.21% | 359B | |
+17.02% | 323B | |
+5.01% | 289B | |
+13.68% | 234B | |
+3.81% | 198B | |
-10.63% | 194B | |
+3.98% | 167B |
- Stock Market
- Equities
- SBFM Stock